PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 130 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2016. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $23,837,000 | -44.4% | 776,456 | +21.3% | 0.00% | -42.9% |
Q3 2016 | $42,908,000 | +147.2% | 639,937 | +9.8% | 0.01% | +133.3% |
Q2 2016 | $17,355,000 | +1.0% | 582,564 | -0.4% | 0.00% | 0.0% |
Q1 2016 | $17,181,000 | -61.6% | 584,979 | +2.5% | 0.00% | -57.1% |
Q4 2015 | $44,754,000 | +0.6% | 570,847 | -3.3% | 0.01% | -12.5% |
Q3 2015 | $44,484,000 | -35.3% | 590,290 | +0.3% | 0.01% | -27.3% |
Q2 2015 | $68,730,000 | -48.8% | 588,693 | +3.5% | 0.01% | -47.6% |
Q1 2015 | $134,235,000 | +27.7% | 568,529 | +2.4% | 0.02% | +23.5% |
Q4 2014 | $105,119,000 | -20.4% | 555,391 | +0.4% | 0.02% | -22.7% |
Q3 2014 | $132,027,000 | +235.2% | 553,410 | -7.3% | 0.02% | +214.3% |
Q2 2014 | $39,392,000 | -33.4% | 596,848 | +5.2% | 0.01% | -30.0% |
Q1 2014 | $59,111,000 | +18.4% | 567,607 | +17.7% | 0.01% | +11.1% |
Q4 2013 | $49,923,000 | +207.6% | 482,204 | +59.5% | 0.01% | +200.0% |
Q3 2013 | $16,228,000 | +41.9% | 302,414 | +17.3% | 0.00% | +50.0% |
Q2 2013 | $11,440,000 | – | 257,825 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
TOBAM | 318,384 | $23,994,000 | 0.94% |
Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |